EMG
CORT icon

Ellington Management Group’s Corcept Therapeutics CORT Stock Holding History

Ellington Management Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,400
Closed -$136K – 116
2020
Q1 		$136K Buy
+11,400
New +$141K 0.03% 478
2016
Q4 		– Sell
-25,800
Closed -$168K – 579
2016
Q3 		$168K Buy
25,800
+4,100
+19% +$23.8K 0.05% 573
2016
Q2 		$118K Buy
+21,700
New +$113K 0.16% 206

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ellington Management Group's CORT Position: Q2 2020 in Review

Ellington Management Group sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 11,400 shares — an estimated $136K sold.

Ellington Management Group first reported a position in CORT in Q2 2016 and held it in 3 quarters. The position peaked at $168K in Q3 2016. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

  • Ellington Management Group reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 11,400 Corcept Therapeutics shares in Q2 2020, an estimated $136K.
  • Ellington Management Group first reported a position in Corcept Therapeutics in Q2 2016 and held it in 3 quarters.
  • Ellington Management Group's Corcept Therapeutics position peaked at $168K in Q3 2016.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.